| Name | Title | Contact Details |
|---|
Centre for Commercialization of Regenerative Medicine , a Canadian not-for-profit organization funded by the Government of Canada`s Networks of Centres of Excellence program, the Province of Ontario, and leading academic and industry partners, supports the development of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy. CCRM aims to accelerate the translation of scientific discovery into marketable products for patients with specialized teams funding, and infrastructure. CCRM sources and evaluates intellectual property from around the globe, offers various consulting services, conducts development projects with partners, and establishes new companies built around strategic bundles of intellectual property. CCRM is the commercialization partner of the Ontario Institute for Regenerative Medicine and the University of Toronto`s Medicine by Design. CCRM is hosted by the University of Toronto and was launched in Toronto`s Discovery District on June 14, 2011.
Our Q Exam is based on landmark systems biology research done at Stanford University. In about 75 minutes, we take blood, saliva, urine and a non-invasive whole-body scan from which we measure over 3000 clinically-relevant genetic, chemical, and anatomical biomarkers to build the world`s most comprehensive quantitative snapshot of your health at a point in time.
Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company`s lead program, repotrectinib, is a next-generation kinase inhibitor targeting genetic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib has shown antitumor activity and durable responses among kinase-naïve and pre-treated patients, and is expected to enter a registrational study in the second half of 2019. Turning Point`s kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to overcome treatment resistance common in other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.
Chiasma improves the lives of patients by transforming injectable drugs into oral medications. The company`s proprietary, clinically validated Transient Permeability Enhancer (TPE®) technology enables intestinal absorption of molecules that previously had limited intestinal bioavailability. Chiasma focuses on peptide drugs, which serve a large market that is currently served only by injectables. Oral formulations offer numerous advantages, including consistent dosing and the elimination of administration site reactions. Chiasma’s lead investigational candidate, octreotide capsules, is being developed for the treatment of acromegaly.
Welcome to a different kind of CRO. Bringing your product to market takes something different. At Rho, we`re experienced, creative problem-solvers who provide outstanding clinical research fueled by our unique team approach. Our dedication to collaboration makes your clinical trials and programs run smarter and more efficiently.